Anika Therapeutics (AKP) AI Stock Analysis

Company Guidance

For 2026, Anika raised total company revenue growth guidance to 6% to 10% from 5% to 10%, expects OEM channel revenue growth of 5% to 9% from 0% to 5% previously, and expects commercial channel growth of 9% to 13% from 12% to 18% previously; adjusted EBITDA margin guidance increased to 15% to 17% from 13% to 17%. For 2027, total company revenue growth is reaffirmed at flat to 5%, commercial channel revenue growth was corrected to 5% to 15%, and OEM revenue is expected to be flat to modestly lower, with pricing declines embedded in guidance; forward guidance does not include any US HYALOFAST sales. The 2026 adjusted EBITDA impact from investment in regenerative solutions is now expected to be closer to $8 million versus $10 million previously, and the company expects positive operating cash flow in the fourth quarter, with CapEx investments in the fourth quarter and next year. The CINGAL NDA is expected to be submitted before year-end 2027, with the bioequivalence study report expected in the first quarter of 27; the Hyvisc agreement is expected to provide $8 million in payments, including a $4 million upfront payment expected in the first quarter of 2027 and the remaining $4 million tied to commercial volumes.